What question did this study set out to answer?

To evaluate treatment patterns and overall survival in HR+/HER2- metastatic breast cancer treated with chemotherapy after endocrine therapy.

Abstract PS1-11-03: Real-world treatment patterns and overall survival in patients with HR+/HER2- metastatic breast cancer treated with chemotherapy following endocrine therapy in the US

View Full Paper

Ask AI

Bookmark

Authors

Observational study reveals poor overall survival in HR+/HER2- metastatic breast cancer after chemotherapy following endocrine therapy.

To evaluate treatment patterns and overall survival in HR+/HER2- metastatic breast cancer treated with chemotherapy after endocrine therapy.
Retrospective cohort study using the Komodo Research Database from 2016 to 2024.
Identified patients with HR+/HER2- metastatic breast cancer who received chemotherapy after endocrine therapy.
Kaplan-Meier method used to assess real-world overall survival from chemotherapy initiation.
1,371 patients identified, median age 59 years, majority were female (98%) and commercially insured (67.8%).
Median real-world overall survival was 18.9 months, with survival rates of 65.0%, 40.5%, and 24.1% at 12, 24, and 36 months, respectively.
Common chemotherapy regimens included capecitabine (60.2%) and paclitaxel (17.3%).

Traina et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark